TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00870545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone support groups
Description: There was one intervention. Participants were enrolled in one of 14 telephone groups (each with a trained Group Leader and 6 participants) will focus on education, training in and practice of coping skills and cognitive restructuring (identifying and re-shaping negative and destructive thoughts), and support through 12 hour-long structured sessions. The content, modeled on Soldier BATTLEMIND, targets readjustment concepts based on the letters of BATTLEMIND, including Bonds, Adding and subtracting family roles, Taking control, Talking it out, Loyalty and commitment, Emotional balance, Mental health and readiness, Independence and interdependence, Navigating the system, Denial of self and a concluding session entitled Moving forward.
Study: NCT00524472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-normoglycemic clamp
Description: Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.

Intervention type: OTHER
Group type: OTHER
Intervention: insulin at the standard of care levels
Description: Subjects will be administered insulin at the standard of care levels established by the participating institution.
Study: NCT02178696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, identified as placebo to participants
Description: White tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, identified as placebo to participants
Description: White tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celexa or other antidepressant as clinically indicated
Description: Open label s-citalopram, 20 mg start up dose, increasing to 40 mg as clinically indicated; If prior non-response to this medication is noted by the patient, alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celexa or other antidepressant as clinically indicated
Description: Open label s-citalopram, 20 mg start up dose, increasing to 40 mg as clinically indicated; If prior non-response to this medication is noted by the patient, alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, identifed to participants as Active medication
Description: Blue Capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, identifed to participants as Active medication
Description: Blue Capsule
Study: NCT04522479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change the injection time of long acting GnRH-a
Description: The whole dose of long acting GnRH-a drug was changed to be injected on day 21st-23rd day of menstruation
Study: NCT02353728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study: NCT04492085

Intervention type: OTHER
Intervention: Questionnaire survey
Description: A customized questionnaire will be delivered by the social software WeChat to explore the prevalence, potential reasons and solutions of workplace violence against physicians of obstetrics and gynecology in China

Intervention type: OTHER
Intervention: Questionnaire survey
Description: A customized questionnaire will be delivered by the social software WeChat to explore the prevalence, potential reasons and solutions of workplace violence against physicians of obstetrics and gynecology in China
Study: NCT02758392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61178104 Intravenous
Description: Participants will receive JNJ-61178104 Intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61178104 Intravenous
Description: Participants will receive JNJ-61178104 Intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61178104 Intravenous
Description: Participants will receive JNJ-61178104 Intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61178104 Subcutaneous
Description: Participants will receive JNJ-61178104 Subcutaneously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo on Day 1.
Study: NCT04492085

Intervention type: OTHER
Intervention: Questionnaire survey
Description: A customized questionnaire will be delivered by the social software WeChat to explore the prevalence, potential reasons and solutions of workplace violence against physicians of obstetrics and gynecology in China
Study: NCT00486824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.
Study: NCT04499989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH
Description: 3 vaginal tablet of isonicotinic acid hydrazide self inserted 12 hours before IUD insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 3 vaginal tablet of Placebo Comparator self inserted 12 hours before IUD insertion
Study: NCT00595010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare
Description: Treatment will be based on an updated version of the SafeCare program, which specifically addresses parenting and discipline associated with child physical abuse. Participants will receive services from Comprehensive Home-Based Services.
Study: NCT02650102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: a kind of antipsychotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: a kind of antipsychotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: a kind of antipsychotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: a kind of antipsychotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: a kind of antipsychotics
Study: NCT01408459

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tomato Product
Description: Motivational Telephone Counseling weekly
Study: NCT02063737

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Text-message assessments only
Description: Text message assessments only. No intervention for high level fatigue.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-message interventions for high level fatigue
Description: Intervention messages to promote alertness while on duty at work including activities. Additionally at the end of the shift, participants were queried on their adoption of the suggested activities and perception of the activities' effectiveness.
Study: NCT05277844

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local Consolidative Radiation Therapy
Description: Local consolidative radiation therapy to loco-regional disease and all Oligometastatic sites in addition to TKI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TKI
Description: TKI
Study: NCT02270502

Intervention type: DEVICE
Intervention: Ultrasound Philips CX50
Description: The Philips CX50 ultrasound system is used to measure muscle size of the patients. We will measure the area and diameter of the rectus femoris muscle via ultrasound.

Intervention type: OTHER
Intervention: Frailty Index Questionnaire
Description: Frailty Index Questionnaire is a clinical tool to assess frailty in patients. We will ask patients to answer the questionnaire, including clarification that the questionnaire assesses the patient's pre-admission condition. The presence of a frail characteristic will be scored as 1 point. Most variables will be dichotomized (e.g. 1 point when a frail characteristic will be present and 0 points when frail characteristic will be not present).The Frailty Index will be calculated as the total number of frail characteristics of the patient divided by the total number of variables (n=50).
Study: NCT05277844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI
Description: TKI
Study: NCT02270502

Intervention type: OTHER
Intervention: Muscle strength tests
Description: MRC score is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement.
Study: NCT03775915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: A visual representation of the participants brain activity during movement of their affected hand in the MRI scanner.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Neurofeedback
Description: A visual representation of brain activity pre-recorded from a previous participant
Study: NCT02152384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study: NCT00941447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: There is a physical Activity of 150 minutes/week of moderate-intense physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: There is a physical Activity of 150 minutes/week of moderate-intense physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulatory Approaches
Description: Participants in this arm will receive extensive feedback based on their self-monitoring diary in which the researcher will be reinforced in areas that they are doing well in regarding their blood glucose and also assist in problem solving in areas that need improvement.
Study: NCT02207777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Description: A surgical procedure to help subjects lose approximately 16-18% (with a range of 16-25%) of their body weight.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-calorie diet
Description: Subjects will meet with a dietitian and/or behaviorist over approximately 6 months to lose approximately 16-18% (with a range of 16-25%) of their body weight.
Study: NCT03483714

Intervention type: PROCEDURE
Intervention: Spinal Manipulation
Description: HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints

Intervention type: PROCEDURE
Intervention: Spinal Manipulation
Description: HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints

Intervention type: PROCEDURE
Intervention: Spinal Manipulation
Description: HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints
Study: NCT01330745

Intervention type: OTHER
Group type: OTHER
Intervention: sublingual microcirculatory evaluation
Description: TNF, ICAM, syndecan-1, heparan sulfate
Study: NCT04471805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial direct current stimulation 4 mA
Description: Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation 4 mA
Description: Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
Study: NCT04323514

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 10 gr of vitamin C intravenously in addition to conventional therapy.
Study: NCT03788707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive leg raising
Description: After 30 seconds of lying flat, volunteers will have passive leg raising to 45 degrees. Expired CO2 will be measured via a face mask before and after leg raising.
Study: NCT00783185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cannabis-Consumption-Reduction-Training
Description: 8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social competence Training
Description: 8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
Study: NCT03848741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Exercise Control
Description: Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
Study: NCT00395161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: 0.2 mg/kg/dose IV every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants \< or equal to one year of age, and 20 mg/day elemental zinc for patients \> 1 year of age)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: one enteral dose daily of glutamine 0.3 gm/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium
Description: one enteral dose daily of selenium (40 μg for infants \< 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children \> 13 years)
Study: NCT00408408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2 IV
Study: NCT00395161

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: equivalent volume of intravenous saline
Study: NCT02293070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed Enhanced Cardiac Magnetic Resonance Imaging
Description: Subjects in this study get a Delayed Enhanced Cardiac Magnetic Resonance Imaging 2-6 weeks after they undergo cryoablation for atrial fibrillation. This MRI is compared to the pre-procedure cardiac MRI to determine if it possible to visualize the cryoablation lesions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: All subjects in this study undergo a cryoballoon ablation procedure to achieve pulmonary vein isolation for the purposes of treatment of atrial fibrillation
Study: NCT01525147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YHB1411-2: Level 2
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YHB1411-2: Level 3
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YHB1411-2: Level 4
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YHB1411-2: Level 5
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion
Study: NCT00395161

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterile water
Description: equivalent volume of sterile water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: selenium
Description: equivalent volume of sterile water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: whey-protein
Description: one enteral dose daily of whey-protein
Study: NCT02899962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 aerosol foam
Description: LEO 90100 aerosol foam twice weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 90100 aerosol foam vehicle
Description: LEO 90100 aerosol foam vehicle twice weekly
Study: NCT03180281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP4
Description: sitagliptin phosphate 100mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin Glargine or detemir 0.2U/kg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SU
Description: Glimepiride 1-2mg qd
Study: NCT06499675

Intervention type: PROCEDURE
Intervention: sleeve gastrectomy
Description: sleeve gastrectomy / bariatric surgery

Intervention type: PROCEDURE
Intervention: Liver Biopsy
Description: intraoperative liver biopsy
Study: NCT03147430

Intervention type: OTHER
Intervention: Biomarkers
Description: Experimentally discover putative plasma markers for detecting early, stage I breast cancer in the setting of a suspicious mammogram and distinguish those cancers from benign lesions b) verify the putative markers through molecular profiling; and c) validate the markers by mass spectrometry.

Intervention type: OTHER
Intervention: Biomarkers
Description: Experimentally discover putative plasma markers for detecting early, stage I breast cancer in the setting of a suspicious mammogram and distinguish those cancers from benign lesions b) verify the putative markers through molecular profiling; and c) validate the markers by mass spectrometry.
Study: NCT01938495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuRx® Diaphragm Pacing System™ (DPS)
Description: The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
Study: NCT01613768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study: NCT03142191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 is a potent, selective inhibitor of JNK.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 is a potent, selective inhibitor of JNK.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 is a potent, selective inhibitor of JNK.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02017015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel at 125 mg/m\^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at 1000 mg/m\^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
Study: NCT01023035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800 mg given three times a day (TID), orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800 mg given three times a day (TID), orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800 mg given three times a day (TID), orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (PEG2b)
Description: 1.5 µg/kg/week given subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (PEG2b)
Description: 1.5 µg/kg/week given subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (PEG2b)
Description: 1.5 µg/kg/week given subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW), with dose adjustment as necessary to achieve and maintain serum hemoglobin levels of 10-12 g/dL
Study: NCT03672227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mealtime Matters Training
Description: This training will address common issues that Head Start teachers including how to deal with picky eaters, in addition to education about the nutritional needs of pre-school aged children.